The Current Ratio as of December 2024 (TTM) for Nuvectis Pharma, Inc. (NVCT) is 2.74

According to Nuvectis Pharma, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 2.74. This represents a change of -9.58% compared to the average of 3.03 of the last 4 quarters.

Nuvectis Pharma, Inc. (NVCT) Historical Current Ratio (quarterly & annually)

How has NVCT Current Ratio performed in the past?

The mean historical Current Ratio of Nuvectis Pharma, Inc. over the last ten years is 2.11. The current 2.74 Current Ratio has changed 12.86% with respect to the historical average. Over the past ten years (40 quarters), NVCT's Current Ratio was at its highest in in the June 2021 quarter at 18.54. The Current Ratio was at its lowest in in the March 2021 quarter at 0.

Nuvectis Pharma, Inc. (NVCT) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Nuvectis Pharma, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Nuvectis Pharma, Inc. (NVCT) Average Current Ratio

How has NVCT Current Ratio performed in the past?

The current Current Ratio of Nuvectis Pharma, Inc. (NVCT) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Nuvectis Pharma, Inc. (NVCT) Current Ratio vs. Peers

How is NVCT’s Current Ratio compared to its peers?

Nuvectis Pharma, Inc.’s Current Ratio is less than Replimune Group, Inc. (10.11), less than Lyra Therapeutics, Inc. (3.64), less than Kronos Bio, Inc. (8.32), less than Gossamer Bio, Inc. (6.74), less than Olema Pharmaceuticals, Inc. (7.10), less than Larimar Therapeutics, Inc. (13.10), less than Centessa Pharmaceuticals plc (21.52), less than Orchestra BioMed Holdings, Inc. (4.23), less than Monte Rosa Therapeutics, Inc. (6.03), less than NewAmsterdam Pharma Company N.V. (10.61), greater than Inventiva S.A. (0.96), less than Cullinan Oncology, Inc. (24.46), less than Compass Therapeutics, Inc. (31.84), less than Ikena Oncology, Inc. (15.32), less than Aerovate Therapeutics, Inc. (8.78), less than Eliem Therapeutics, Inc. (0), less than Decibel Therapeutics, Inc. (4.81), less than Anebulo Pharmaceuticals, Inc. (3.45), less than Werewolf Therapeutics, Inc. (10.10), less than Edgewise Therapeutics, Inc. (26.35), less than Celcuity Inc. (10.36), less than C4 Therapeutics, Inc. (6.31),

Build a custom stock screener for Nuvectis Pharma, Inc. (NVCT) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Nuvectis Pharma, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Nuvectis Pharma, Inc. (NVCT) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Nuvectis Pharma, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.